Atomoxetine increases salivary cortisol in healthy volunteers

Journal of Psychopharmacology

Volumn 21, Issue 5, 2007, Pages 545-549

  Chamberlain, Samuel R ^a,b   Müller, Ulrich ^a,b,c   Cleary, Sarah ^d   Robbins, Trevor W ^b,c   Sahakian, Barbara J ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UK   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

ADHD; Depression; HPA; Hyperactivity; Impulsivity; Neuroendocrine; Noradrenaline

Indexed keywords

ATOMOXETINE; CITALOPRAM; HYDROCORTISONE; NORADRENALIN; PLACEBO;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE; CARDIOVASCULAR PARAMETERS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE SYSTEM; NEUROPSYCHIATRY; NORMAL HUMAN; PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SALIVA ANALYSIS; SALIVA LEVEL;

ADMINISTRATION, ORAL; ADRENERGIC UPTAKE INHIBITORS; BLOOD PRESSURE; CAPSULES; CITALOPRAM; DOUBLE-BLIND METHOD; HEART RATE; HUMANS; HYDROCORTISONE; MALE; PITUITARY-ADRENAL FUNCTION TESTS; PROPYLAMINES; REFERENCE VALUES; SALIVA; SALIVARY GLANDS; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 34547126684     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881106075274     Document Type: Article

References (30)

1. Aardal-Eriksson E., Karlberg B.E., Holm A.C. (1998) Salivary cortisol - an alternative to serum cortisol determinations in dynamic function tests. Clin Chem Lab Med 36 (4). 215 - 222
2. Beck A.T., Beamesderfer A. (1974) Assessment of depression: the depression inventory. Mod Probl Pharmacopsychiatry 7 (0). 151 - 169
3. Biederman J., Spencer T., Wilens T. (2004) Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol 7 (1). 77 - 97
4. Chamberlain S.R., Sahakian B. (2005) Neuropsychological assessment of mood disorder. Clin Neuropsych Journ Treat Eval 2 (3). 137 - 148
5. Chamberlain S.R., Sahakian B.J. (2004) Cognition in mania and depression: psychological models and clinical implications. Curr Psych Rep 6 (6). 451 - 458
6. Chamberlain S.R., Muller U., Blackwell A.D., Clark L.T., Robbins W., Sahakian B.J. (2006) Neurochemical modulation of response inhibition and probabilistic learning in humans. Science 311 (5762). 861 - 863
7. Curtis A.L., Bello N.T., Connolly K.R., Valentino R.J. (2002) Corticotropin-releasing factor neurones of the central nucleus of the amygdala mediate locus coeruleus activation by cardiovascular stress. J Neuroendocrinol 14 (8). 667 - 682
8. Faraone S.V., Biederman J., Spencer T., Michelson D., Adler L., Reimherr F., Glatt S.J. (2005) Efficacy of atomoxetine in adult attentiondeficit/ hyperactivity disorder: a drug-placebo response curve analysis. Behav Brain Funct 1: 16
9. Goodyer I.M., Herbert J., Altham P.M., Pearson J., Secher S.M., Shiers H.M. (1996) Adrenal secretion during major depression in 8- to 16-year-olds, I. Altered diurnal rhythms in salivary cortisol and dehydroepiandrosterone (DHEA) at presentation. Psychol Med 26 (2). 245 - 256
10. Goodyer I.M., Herbert J., Tamplin A. (2003) Psychoendocrine antecedents of persistent first-episode major depression in adolescents: a community-based longitudinal enquiry. Psychol Med 33 (4). 601 - 610
11. Harris T.O., Borsanyi S., Messari S., Stanford K., Cleary S.E., Shiers H.M., Brown G.W., Herbert J. (2000) Morning cortisol as a risk factor for subsequent major depressive disorder in adult women. Br J Psychiatry 177: 505 - 510
12. Hennig J., Lange N., Haag A., Rohrmann S., Netter P. (2000) Reboxetine in a neuroendocrine challenge paradigm: evidence for high cortisol responses in healthy volunteers scoring high on subclinical depression. Int J Neuropsychopharmacol 3 (3). 193 - 201
13. Hill S.A., Taylor M.J., Harmer C.J., Cowen P.J. (2003) Acute reboxetine administration increases plasma and salivary cortisol. J Psychopharmacol 17 (3). 273 - 275
14. Kirschbaum C., Hellhammer D.H. (1994) Salivary cortisol in psychoneuroendocrine research: recent developments and applications. Psychoneuroendocrinology 19 (4). 313 - 333
15. Lile J.A., Stoops W.W., Durell T.M., Glaser P.E., Rush C.R. (2006) Discriminative-stimulus, self-reported, performance, and cardiovascular effects of atomoxetine in methylphenidate-trained humans. Exp Clin Psychopharmacol 14 (2). 136 - 147
16. Lo M.S., Ng M.L., Azmy B.S., Khalid B.A. (1992) Clinical applications of salivary cortisol measurements. Singapore Med J 33 (2). 170 - 173
17. Nadeem H S., Attenburrow M J., Cowen P J. (2004) Comparison of the effects of citalopram and escitalopram on 5-Ht-mediated neuroendocrine responses. Neuropsychopharmacology 29 (9). 1699 - 1703
18. Nelson H.E. (1982) National Adult Reading Test (NART). Test Manual. NFER-Nelson, Windsor
19. Nutt D., Middleton H., Franklin M. (1987) The neuroendocrine effects of oral imipramine. Psychoneuroendocrinology 12 (5). 367 - 375
20. Plotsky P.M. (1987) Facilitation of immunoreactive corticotropin- releasing factor secretion into the hypophysial-portal circulation after activation of catecholaminergic pathways or central norepinephrine injection. Endocrinology 121 (3). 924 - 930
21. Sauer J.M., Ring B.J., Witcher J.W. (2005) Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet 44 (6). 571 - 590
22. Schule C., Baghai T., Schmidbauer S., Bidlingmaier M., Strasburger C J., Laakmann G. (2004) Reboxetine acutely stimulates cortisol, ACTH, growth hormone and prolactin secretion in healthy male subjects. Psychoneuroendocrinology 29 (2). 185 - 200
23. Schule C., Baghai T.C., Eser D., Zwanzger P., Jordan M., Buechs R., Rupprecht R. (2006) Time course of hypothalamic-pituitary-adrenocortical axis activity during treatment with reboxetine and mirtazapine in depressed patients. Psychopharmacology (Berl) 186 (4). 601 - 611
24. Seifritz E., Baumann P., Muller M.J., Annen O., Amey M., Hemmeter U., Hatzinger M., Chardon F., Holsboer-Trachsler E. (1996) Neuroendocrine effects of a 20-mg citalopram infusion in healthy males. A placebo-controlled evaluation of citalopram as 5-HT function probe. Neuropsychopharmacology 14 (4). 253 - 263
25. Sheline Y.I. (2000) 3D MRI studies of neuroanatomic changes in unipolar major depression: the role of stress and medical comorbidity. Biol Psychiatry 48 (8). 791 - 800
26. Stahl S.M. (2003) Neurotransmission of cognition, part 2. Selective NRIs are smart drugs: exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition. J Clin Psychiatry 64 (2). 110 - 111
27. Thomason C., Michelson D. (2004) Atomoxetine - treatment of attention deficit hyperactivity disorder: beyond stimulants. Drugs Today (Barc) 40 (5). 465 - 473
28. Tse W.S., Bond A.J. (2005) Sex differences in cortisol response to reboxetine. J Psychopharmacol 19 (1). 46 - 50
29. van Stegeren A., Rohleder N., Everaerd W., Wolf O.T. (2006) Salivary alpha amylase as marker for adrenergic activity during stress: Effect of betablockade. Psychoneuroendocrinology 31 (1). 137 - 141
30. Varghese F.P., Brown E.S. (2001) The Hypothalamic-Pituitary-Adrenal Axis in Major Depressive Disorder: A Brief Primer for Primary Care Physicians. Prim Care Companion J Clin Psychiatry 3 (4). 151 - 155